<?xml version="1.0" encoding="UTF-8"?>
<p>Participants were evaluated at 18-month intervals. At each assessment, demographic, cognitive and clinical data were collected as well as blood samples. For the clinical assessment, a semi-structured interview collected information on areas such as symptom history, level of education and comorbid disease. Motor severity was assessed using the Movement Disorder Society Unified Parkinsonâ€™s Disease Rating Scale (MDS-UPDRS) Part III [
 <xref rid="ref048" ref-type="bibr">48</xref>] and the Hoehn and Yahr (HY) scale [
 <xref rid="ref049" ref-type="bibr">49</xref>]. Data on medication usage included levodopa equivalent daily dose (LEDD) at the time of recruitment [
 <xref rid="ref050" ref-type="bibr">50</xref>]. Mild Cognitive Impairment (PD-MCI) was assessed using modified MDS Level 2 criteria [
 <xref rid="ref051" ref-type="bibr">51</xref>], whereby PD-MCI was classified using 1.5 SDs below normative values [
 <xref rid="ref044" ref-type="bibr">44</xref>].
</p>
